Predictive factors for disease progression in hospitalized patients with coronavirus disease 2019 in Wuhan, China.
Adult
Aged
Aged, 80 and over
Betacoronavirus
C-Reactive Protein
/ analysis
COVID-19
Comorbidity
Coronavirus Infections
/ blood
Cytokines
/ blood
Disease Progression
Female
Hospitalization
/ statistics & numerical data
Humans
Lymphocyte Count
Male
Middle Aged
Multivariate Analysis
Pandemics
Pneumonia, Viral
/ blood
Predictive Value of Tests
Prognosis
Retrospective Studies
Risk Factors
SARS-CoV-2
Sex Factors
Coronavirus disease 2019
Predictive factors
Prognosis
Journal
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology
ISSN: 1873-5967
Titre abrégé: J Clin Virol
Pays: Netherlands
ID NLM: 9815671
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
05
03
2020
revised:
10
04
2020
accepted:
26
04
2020
pubmed:
4
5
2020
medline:
17
6
2020
entrez:
4
5
2020
Statut:
ppublish
Résumé
A few studies have revealed the clinical characteristics of hospitalized patients with COVID-19. However, predictive factors for the outcomes remain unclear. Attempted to determine the predictive factors for the poor outcomes of patients with COVID-19. This is a single-center, retrospective study. Clinical, laboratory, and treatment data were collected and analyzed from 111 hospitalized patients with laboratory-confirmed COVID-19 in Union Hospital. The gathered data of discharged and deteriorated patients were compared. Among these 111 patients, 93 patients were discharged and 18 patients were deteriorated. The lymphocyte count (0.56 G/L [0.47-0.63] vs 1.30 G/L [0.95-1.65]) was lower in the deteriorated group than those in the discharged group. The numbers of pulmonary lobe involved (5.00 [5.00-5.00] vs 4.00 [2.00-5.00]), serum C-reactive protein (CRP, 79.52 mg/L [61.25-102.98] vs 7.93 mg/L [3.14-22.50]), IL-6 (35.72 pg/mL [9.24-85.19] vs 5.09 pg/mL [3.16-9.72]), and IL-10 (5.35 pg/mL [4.48-7.84] vs 3.97 pg/mL [3.34-4.79]) concentrations in deteriorated patients were elevated compared with discharged patients. Multivariate logistic regression analysis showed that male gender (OR, 24.8 [1.8-342.1]), comorbidity (OR, 52.6 [3.6-776.4]), lymphopenia (OR, 17.3 [1.1-261.8]), and elevated CRP (OR, 96.5 [4.6-2017.6]) were the independent risk factors for the poor prognosis in COVID-19 patients. This finding would facilitate the early identification of high-risk COVID-19 patients.
Sections du résumé
BACKGROUND
A few studies have revealed the clinical characteristics of hospitalized patients with COVID-19. However, predictive factors for the outcomes remain unclear.
OBJECTIVE
Attempted to determine the predictive factors for the poor outcomes of patients with COVID-19.
STUDY DESIGN
This is a single-center, retrospective study. Clinical, laboratory, and treatment data were collected and analyzed from 111 hospitalized patients with laboratory-confirmed COVID-19 in Union Hospital. The gathered data of discharged and deteriorated patients were compared.
RESULTS
Among these 111 patients, 93 patients were discharged and 18 patients were deteriorated. The lymphocyte count (0.56 G/L [0.47-0.63] vs 1.30 G/L [0.95-1.65]) was lower in the deteriorated group than those in the discharged group. The numbers of pulmonary lobe involved (5.00 [5.00-5.00] vs 4.00 [2.00-5.00]), serum C-reactive protein (CRP, 79.52 mg/L [61.25-102.98] vs 7.93 mg/L [3.14-22.50]), IL-6 (35.72 pg/mL [9.24-85.19] vs 5.09 pg/mL [3.16-9.72]), and IL-10 (5.35 pg/mL [4.48-7.84] vs 3.97 pg/mL [3.34-4.79]) concentrations in deteriorated patients were elevated compared with discharged patients. Multivariate logistic regression analysis showed that male gender (OR, 24.8 [1.8-342.1]), comorbidity (OR, 52.6 [3.6-776.4]), lymphopenia (OR, 17.3 [1.1-261.8]), and elevated CRP (OR, 96.5 [4.6-2017.6]) were the independent risk factors for the poor prognosis in COVID-19 patients.
CONCLUSIONS
This finding would facilitate the early identification of high-risk COVID-19 patients.
Identifiants
pubmed: 32361327
pii: S1386-6532(20)30134-7
doi: 10.1016/j.jcv.2020.104392
pmc: PMC7187844
pii:
doi:
Substances chimiques
Cytokines
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104392Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.
Références
Biochem J. 2005 Nov 15;392(Pt 1):135-43
pubmed: 16048439
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
J Emerg Med. 1999 Nov-Dec;17(6):1019-25
pubmed: 10595891
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Hypertension. 2004 May;43(5):970-6
pubmed: 15007027
J Virol. 1999 Sep;73(9):7853-9
pubmed: 10438879
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
N Engl J Med. 2013 Aug 1;369(5):407-16
pubmed: 23782161
J Infect. 2016 Nov;73(5):468-475
pubmed: 27519621
Inflamm Res. 2019 Jan;68(1):39-46
pubmed: 30288556
Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767
pubmed: 29161116
Virology. 2001 Sep 15;288(1):1-7
pubmed: 11543652
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Int J Mol Med. 2004 Aug;14(2):311-5
pubmed: 15254784
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
PLoS Med. 2006 Sep;3(9):e343
pubmed: 16968120
N Engl J Med. 2003 May 15;348(20):1986-94
pubmed: 12682352
Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):E5444-E5453
pubmed: 28630327
J Exp Med. 2000 Nov 6;192(9):1353-64
pubmed: 11067883
Biochem Biophys Res Commun. 2020 Feb 17;:
pubmed: 32081428
Lancet Respir Med. 2017 Jun;5(6):500-511
pubmed: 28522352
Clin Exp Pharmacol Physiol. 2010 Jan;37(1):e1-6
pubmed: 19793108
FASEB J. 2019 Aug;33(8):8865-8877
pubmed: 31034780